Skip to main content
Year archive

BioSenic SA — 2020 filings

All 81 regulatory filings released by BioSenic SA (BIOS) in 2020, sourced directly from the official regulator.

81 Filings
2020 Period
2020 filings (81)
Filing Released Lang
PR_2020-12-24_BOTHE_Transparency Notification_CPH_EN_Final.pdf
Major Shareholding Notification
2020-12-24 English
PR_2020-12-24_BOTHE_Transparency Notification_CPH_FR_Final.pdf
Major Shareholding Notification
2020-12-24 French
BOTHE_CPH_TR-1_2020-12-22.pdf
Major Shareholding Notification
2020-12-24 French
PR_2020-12-24_BOTHE_PIPE-Denominator_EN_Final.pdf
Share Issue/Capital Change
2020-12-24 English
PR_2020-12-24_BOTHE_PIPE-Denominator_FR_Final.pdf
Major Shareholding Notification
2020-12-24 French
Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
Legal Proceedings Report
2020-12-22 English
Bone Therapeutics finalise le recrutement et le traitement des patients dans son étude pivot de Phase III évaluant le JTA-004 dans l’arthrose du genou
Regulatory Filings
2020-12-22 French
Bone Therapeutics _Private Placement 2020_Rapport special BoD_signe.pdf
Capital/Financing Update
2020-12-11 French
Bone Therapeutics announces pricing of private placement
Capital/Financing Update
2020-12-11 English
Bone Therapeutics réalise un placement privé
Capital/Financing Update
2020-12-11 French
Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent
M&A Activity
2020-11-16 English
Finalisation de l’acquisition de SCTS, la filiale de production de thérapie cellulaire de Bone Therapeutics, par Catalent
M&A Activity
2020-11-16 French
Bone Therapeutics and its collaborators awarded €3 million in funding under the framework of BioWin to develop personalized, tissue engineered bone implants
Regulatory Filings
2020-11-10 English
Bone Therapeutics et ses partenaires reçoivent un financement de 3M€ via BioWin pour le développement d’implants osseux personnalisés issus de l’ingénierie tissulaire
Regulatory Filings
2020-11-10 French
PR_2020-10-30_BOTHE_2020-Q3_EN_Final.pdf
Earnings Release Q3 2020
2020-10-30 English
PR_2020-10-30_BOTHE_2020-Q3_FR_Final.pdf
Earnings Release Q3 2020
2020-10-30 French
Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
M&A Activity
2020-10-29 English
Bone Therapeutics signe des accords avec Catalent pour optimiser la production du produit de thérapie cellulaire allogénique ALLOB
M&A Activity
2020-10-29 French
PR_2020-10-23_BOTHE_Transparency Notification_SRIW_EN_Final.pdf
Major Shareholding Notification
2020-10-23 English
PR_2020-10-23_BOTHE_Transparency Notification_SRIW_FR_Final.pdf
Major Shareholding Notification
2020-10-23 French
SRIW_BONE THERAPEUTICS_TR-1_2020-10-16.pdf
Major Shareholding Notification
2020-10-23 French
PR_2020-10-23_BOTHE_CB Denominator_EN_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-10-23 English
PR_2020-10-23_BOTHE_CB Denominator_FR_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-10-23 French
Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
Regulatory Filings
2020-10-20 English
Bone Therapeutics a traité 50% des patients dans son étude pivot de Phase III évaluant le JTA-004 dans l’arthrose du genou
Legal Proceedings Report
2020-10-20 French
Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia
Regulatory Filings
2020-10-05 English
Bone Therapeutics, Link Health et Pregene s’associent pour le développement et la commercialisation de la plateforme de thérapie cellulaire allogénique en Chine et en Asie du Sud-Est
M&A Activity
2020-10-05 French
PR_2020-09-09_BOTHE_CB Denominator_EN_Final.pdf
Share Issue/Capital Change
2020-09-09 English
PR_2020-09-09_BOTHE_CB Denominator_FR_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-09-09 French
PR_2020-08-26_BOTHE_2020H1_EN_Final.pdf
Interim / Quarterly Report H1 2020
2020-08-26 English
PR_2020-08-26_BOTHE_2020H1_FR_Final.pdf
Interim / Quarterly Report H1 2020
2020-08-26 French
BoneTherapeutics_20200826_Interim Financial Report H1 2020_EN_Final.pdf
Interim / Quarterly Report H1 2020
2020-08-26 English
BoneTherapeutics_20200826_Interim Financial Report H1 2020_FR_Final.pdf
Interim / Quarterly Report H1 2020
2020-08-26 French
Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region
Regulatory Filings
2020-08-20 English
Bone Therapeutics agrandit son portefeuille de produits avec le soutien de la Région Wallonne
Regulatory Filings
2020-08-20 French
20200610_BOTHE_AGO_PV_signed.pdf
AGM Information
2020-07-03 French
Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020
AGM Information
2020-06-11 English
Bone Therapeutics annonce les résultats de son Assemblée Générale Ordinaire Annuelle et confirme ses objectifs pour l’année 2020
AGM Information
2020-06-11 French
PR_2020-05-28_BOTHE_Transparency Notification_SRIW_EN_Final.pdf
Major Shareholding Notification
2020-05-29 English
PR_2020-05-28_BOTHE_Transparency Notification_SRIW_FR_Final.pdf
Major Shareholding Notification
2020-05-29 French
PR_2020-05-29_BOTHE_CB Denominator_EN_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-05-29 English
PR_2020-05-29_BOTHE_CB Denominator_FR_Final.pdf
Share Issue/Capital Change
2020-05-29 French
02_BOTHE_AGO_2020-06-10_Procuration_FR.pdf
AGM Information
2020-05-11 French
01_BOTHE_AGO_2020-06-10_Convocation_FR_Final.pdf
AGM Information
2020-05-11 French
08_BOTHE_AGO_2020-06-10_CVs directors.pdf
Board/Management Information
2020-05-11 French
07_BOTHE_AGO_2020-06-10_Comptes Annuels 2019.PDF
Audit Report / Information FY 2019
2020-05-11 French
10_BOTHE_AGO_2020-06-10_Warrant Plan-Template_EN.pdf
Regulatory Filings
2020-05-11 English
10_BOTHE_AGO_2020-06-10_Warrant Plan-Template_FR.pdf
Remuneration Information
2020-05-11 French
09_BOTHE_AGO_2020-06-10_Warrant Plan 2020_EN.pdf
Capital/Financing Update
2020-05-11 English
05_BOTHE_AGO_2020-06-10_Rapport de gestion du CA au 2019-12-31-12_20200428.pdf
Annual Report FY 2019
2020-05-11 French
03_BOTHE_AGM_2020-06-10_Information shareholders rights_EN.pdf
AGM Information
2020-05-11 English
09_BOTHE_AGO_2020-06-10_Warrant Plan 2020_FR.pdf
Capital/Financing Update
2020-05-11 French
02_BOTHE_AGM_2020-06-10_Proxy form_EN.pdf
Proxy Solicitation & Information Statement
2020-05-11 English
06_BOTHE_AGO_2020-06-10_Auditor Report_2019-12-31.pdf
Audit Report / Information FY 2019
2020-05-11 French
01_BOTHE_AGM_2020-06-10_Convening notice_EN_Final.pdf
AGM Information
2020-05-11 English
03_BOTHE_AGO_2020-06-10_Information droits actionnaires_FR.pdf
AGM Information
2020-05-11 French
11_BOTHE_Rapport_spécial_art_7_228_continuité_Final.pdf
AGM Information
2020-05-11 Dutch
PR_2020-05-11_BOTHE_AGO 2019 Notice_EN_Final.pdf
AGM Information
2020-05-11 English
PR_2020-05-11_BOTHE_AGO 2019 Notice_FR_Final.pdf
AGM Information
2020-05-11 French
Bone Therapeutics_20200507_Rapport spécial_art7-198_final-signée.pdf
Capital/Financing Update
2020-05-07 French
Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15 million committed, providing runway into Q2 2021
Capital/Financing Update
2020-05-07 English
Bone Therapeutics renforce sa visibilité financière jusqu’au deuxième trimestre 2021 en levant 4,0 M€ supplémentaires, soit un total de 15,0 M€ engagés
Capital/Financing Update
2020-05-07 French
PR_2020-05-06_BOTHE_2020-Q1_EN_Final.pdf
Interim / Quarterly Report Q1 2020
2020-05-06 English
PR_2020-05-06_BOTHE_2020-Q1_FR_Final.pdf
Interim / Quarterly Report Q1 2020
2020-05-06 French
Bone Therapeutics_20200429_Rapport spécial_art7-198_final-signée.pdf
Capital/Financing Update
2020-04-29 French
Bone Therapeutics secures EUR 11.0 million financing
Capital/Financing Update
2020-04-29 English
Bone Therapeutics sécurise un financement de 11,0 millions d'euros
Capital/Financing Update
2020-04-29 French
AR_2019_Full_EN_v11_Complete.pdf
Annual Report FY 2019
2020-04-29 English
AR_2019_Full_FR_v05_Complete.pdf
Annual Report FY 2019
2020-04-29 French
PR_2020-04-03_BT_CB Denominator_EN_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-04-03 English
PR_2020-04-03_BT_CB Denominator_FR_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-04-03 French
Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates
Regulatory Filings
2020-03-23 English
Bone Therapeutics obtient l’approbation de ses demandes d’essai clinique pour ses deux candidats médicaments principaux
Regulatory Filings
2020-03-23 French
PR_2020-03-11_BT_FY2019_EN_Long_Final.pdf
Earnings Release FY 2019
2020-03-11 English
PR_2020-03-11_BT_FY2019_FR_Long_Final.pdf
Annual Report FY 2019
2020-03-11 French
PR_2020-02-28_BT_CB Denominator_EN_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-02-28 English
PR_2020-02-28_BT_CB Denominator_FR_Final.pdf
Share Issue/Capital Change
2020-02-28 French
PR_2020-01-31_BT_CB Denominator_EN_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-01-31 English
PR_2020-01-31_BT_CB Denominator_FR_Final.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-01-31 French
Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position
Earnings Release FY 2019
2020-01-22 English
Bone Therapeutics annonce ses perspectives d’activité pour 2020 et sa position de trésorerie à fin 2019
Management Reports
2020-01-22 French